S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
NASDAQ:CTMX

CytomX Therapeutics Stock Forecast, Price & News

$6.75
-0.29 (-4.12%)
(As of 11/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.74
$6.96
50-Day Range
$4.83
$7.39
52-Week Range
$4.28
$10.05
Volume
829,162 shs
Average Volume
835,435 shs
Market Capitalization
$440.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.7
30 days | 90 days | 365 days | Advanced Chart
Receive CTMX News and Ratings via Email

Sign-up to receive the latest news and ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


CytomX Therapeutics logo

About CytomX Therapeutics

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

Headlines

CytomX Therapeutics (NASDAQ:CTMX) Announces Earnings Results
November 7, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CTMX
Employees
145
Year Founded
N/A

Sales & Book Value

Annual Sales
$100.36 million
Book Value
$1.71 per share

Profitability

Net Income
$-32.88 million
Net Margins
-108.85%
Pretax Margin
-108.85%

Debt

Price-To-Earnings

Miscellaneous

Free Float
62,248,000
Market Cap
$440.43 million
Optionable
Optionable

Company Calendar

Last Earnings
11/04/2021
Today
11/28/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/23/2022

MarketRank

Overall MarketRank

1.96 out of 5 stars

Medical Sector

658th out of 1,391 stocks

Pharmaceutical Preparations Industry

309th out of 669 stocks

Analyst Opinion: 3.3Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












CytomX Therapeutics (NASDAQ:CTMX) Frequently Asked Questions

Is CytomX Therapeutics a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last twelve months. There are currently 1 sell rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CytomX Therapeutics stock.
View analyst ratings for CytomX Therapeutics
or view top-rated stocks.

How has CytomX Therapeutics' stock price been impacted by COVID-19?

CytomX Therapeutics' stock was trading at $5.87 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CTMX stock has increased by 15.0% and is now trading at $6.75.
View which stocks have been most impacted by COVID-19
.

When is CytomX Therapeutics' next earnings date?

CytomX Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for CytomX Therapeutics
.

How were CytomX Therapeutics' earnings last quarter?

CytomX Therapeutics, Inc. (NASDAQ:CTMX) released its earnings results on Thursday, November, 4th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.05. CytomX Therapeutics had a negative trailing twelve-month return on equity of 65.76% and a negative net margin of 108.85%. During the same quarter in the previous year, the firm earned ($0.32) EPS.
View CytomX Therapeutics' earnings history
.

What price target have analysts set for CTMX?

6 brokerages have issued 1-year price objectives for CytomX Therapeutics' shares. Their forecasts range from $7.00 to $16.00. On average, they anticipate CytomX Therapeutics' share price to reach $13.00 in the next twelve months. This suggests a possible upside of 92.6% from the stock's current price.
View analysts' price targets for CytomX Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are CytomX Therapeutics' key executives?

CytomX Therapeutics' management team includes the following people:
  • Sean A. McCarthy, Chairman, President & Chief Executive Officer (LinkedIn Profile)
  • Carlos E. Campoy, Chief Financial Officer & Senior Vice President
  • Marcia P. Belvin, Senior Vice President & Head-Research
  • Alison L. Hannah, Chief Medical Officer & Senior Vice President
  • Amy C. Peterson, Chief Development Officer & Executive VP

What is Sean A McCarthy's approval rating as CytomX Therapeutics' CEO?

11 employees have rated CytomX Therapeutics CEO Sean A McCarthy on Glassdoor.com. Sean A McCarthy has an approval rating of 65% among CytomX Therapeutics' employees.

What other stocks do shareholders of CytomX Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include Gilead Sciences (GILD), Exelixis (EXEL), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Bristol-Myers Squibb (BMY) and Dynavax Technologies (DVAX).

What is CytomX Therapeutics' stock symbol?

CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."

Who are CytomX Therapeutics' major shareholders?

CytomX Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Point72 Asset Management L.P. (9.66%), BlackRock Inc. (7.74%), Candriam Luxembourg S.C.A. (5.07%), Victory Capital Management Inc. (5.02%), Great Point Partners LLC (2.30%) and Altium Capital Management LP (1.89%).
View institutional ownership trends for CytomX Therapeutics
.

Which major investors are selling CytomX Therapeutics stock?

CTMX stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, Morgan Stanley, Assenagon Asset Management S.A., Dimensional Fund Advisors LP, Citigroup Inc., Two Sigma Advisers LP, Renaissance Technologies LLC, and Point72 Asset Management L.P..
View insider buying and selling activity for CytomX Therapeutics
or view top insider-selling stocks.

Which major investors are buying CytomX Therapeutics stock?

CTMX stock was bought by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Great Point Partners LLC, Victory Capital Management Inc., Altium Capital Management LP, Millennium Management LLC, GSA Capital Partners LLP, AXA S.A., and Goldman Sachs Group Inc..
View insider buying and selling activity for CytomX Therapeutics
or or view top insider-buying stocks.

How do I buy shares of CytomX Therapeutics?

Shares of CTMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CytomX Therapeutics' stock price today?

One share of CTMX stock can currently be purchased for approximately $6.75.

How much money does CytomX Therapeutics make?

CytomX Therapeutics has a market capitalization of $440.43 million and generates $100.36 million in revenue each year. The biotechnology company earns $-32.88 million in net income (profit) each year or ($1.22) on an earnings per share basis.

How many employees does CytomX Therapeutics have?

CytomX Therapeutics employs 145 workers across the globe.

What is CytomX Therapeutics' official website?

The official website for CytomX Therapeutics is www.cytomx.com.

Where are CytomX Therapeutics' headquarters?

CytomX Therapeutics is headquartered at 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080.

How can I contact CytomX Therapeutics?

CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at (605) 515-3185, via email at [email protected], or via fax at 650-351-0353.


This page was last updated on 11/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.